TY - JOUR
T1 - Spatiotemporal relationship between subthreshold amyloid accumulation and aerobic glycolysis in the human brain
AU - Goyal, Manu S.
AU - Gordon, Brian A.
AU - Couture, Lars E.
AU - Flores, Shaney
AU - Xiong, Chengjie
AU - Morris, John C.
AU - Raichle, Marcus E.
AU - L-S. Benzinger, Tammie
AU - Vlassenko, Andrei G.
N1 - Funding Information:
The authors are grateful to our participants. The authors also acknowledge the Vlassenko-Goyal Laboratory, Neuroimaging Laboratory, Knight Alzheimer's Disease Research Center, cyclotron, and imaging staff for making this research possible. Funding for this research was provided by the Barnes-Jewish Hospital Foundation (J.C.M.), Willman Scholar Fund (B.A.G.), the James S. McDonnell Foundation, the McDonnell Center for Systems Neuroscience, the NIH/NIA R01AG053503 (A.G.V. and M.E.R.), R01AG057536 (A.G.V. and M.S.G.), P50AG0005681 (J.C.M.), P01AG026276 (J.C.M. and T.L.S.B.), and P01AG003991 (J.C.M. and T.L.S.B.). Support for Florbetapir-F18 scans at the Knight Alzheimer's Disease Research Center was provided by Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly. The authors would like to thank the Centiloid Project for making data available for additional amyloid imaging.
Funding Information:
Funding for this research was provided by the Barnes-Jewish Hospital Foundation (J.C.M.), Willman Scholar Fund (B.A.G.), the James S. McDonnell Foundation, the McDonnell Center for Systems Neuroscience , the NIH/NIA R01AG053503 (A.G.V. and M.E.R.), R01AG057536 (A.G.V. and M.S.G.), P50AG0005681 (J.C.M.), P01AG026276 (J.C.M. and T.L.S.B.), and P01AG003991 (J.C.M. and T.L.S.B.). Support for Florbetapir-F18 scans at the Knight Alzheimer's Disease Research Center was provided by Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly. The authors would like to thank the Centiloid Project for making data available for additional amyloid imaging.
Funding Information:
Related to this study: Florbetapir-F18 scans were supported by an institutional research grant from Avid Radiopharmaceuticals, a wholly owned subsidiary from Eli Lilly (J.C.M. and T.L.S.B.).
Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/12
Y1 - 2020/12
N2 - In Alzheimer's disease, brain amyloid deposition has a distinct topography that correlates with aerobic glycolysis (AG), that is, the use of glucose beyond that predicted by oxygen consumption. The causes for this relationship remain unclear but might provide crucialinsight into how amyloid deposition begins. Here we develop methods to study the earliest topography of amyloid deposition based on amyloid imaging and investigate its spatiotemporal evolution with respect to the topography of AG in adults. We find that the spatiotemporal dynamics of amyloid deposition are largely explained by 1 factor, defined here as the amyloid topography dissimilarity index (ATDI). ATDI is bimodal, more highly dynamic during early amyloid accumulation, and predicts which individuals will cross a conservative quantitative threshold at least 3–5 years in advance. Using ATDI, we demonstrate that subthreshold amyloid accumulates primarily in regions that have high AG during early adulthood. Our findings suggest that early on-target subthreshold amyloid deposition mirrors its later regional pattern, which best corresponds to the topography of young adult brain AG.
AB - In Alzheimer's disease, brain amyloid deposition has a distinct topography that correlates with aerobic glycolysis (AG), that is, the use of glucose beyond that predicted by oxygen consumption. The causes for this relationship remain unclear but might provide crucialinsight into how amyloid deposition begins. Here we develop methods to study the earliest topography of amyloid deposition based on amyloid imaging and investigate its spatiotemporal evolution with respect to the topography of AG in adults. We find that the spatiotemporal dynamics of amyloid deposition are largely explained by 1 factor, defined here as the amyloid topography dissimilarity index (ATDI). ATDI is bimodal, more highly dynamic during early amyloid accumulation, and predicts which individuals will cross a conservative quantitative threshold at least 3–5 years in advance. Using ATDI, we demonstrate that subthreshold amyloid accumulates primarily in regions that have high AG during early adulthood. Our findings suggest that early on-target subthreshold amyloid deposition mirrors its later regional pattern, which best corresponds to the topography of young adult brain AG.
KW - Aerobic glycolysis
KW - Alzheimer's disease
KW - Brain amyloid
KW - Positron emission tomography
UR - http://www.scopus.com/inward/record.url?scp=85091943413&partnerID=8YFLogxK
U2 - 10.1016/j.neurobiolaging.2020.08.019
DO - 10.1016/j.neurobiolaging.2020.08.019
M3 - Article
C2 - 33011615
AN - SCOPUS:85091943413
SN - 0197-4580
VL - 96
SP - 165
EP - 175
JO - Neurobiology of Aging
JF - Neurobiology of Aging
ER -